期刊文献+

JAK2V617F基因突变与骨髓增殖性肿瘤疾病类型及疾病转化的相关性分析 被引量:6

JAK2V617F Mutation Correlated with Disease Classification and Conversion in Patients with Myeloproliferative Neoplasm
下载PDF
导出
摘要 目的研究骨髓增殖性肿瘤(MPN)中JAK2V617F基因突变与疾病类型及疾病转化的相关性。方法检测我区134例MPN患者JAK2V617F基因,分析基因突变在真性红细胞增多症(PV)、原发性血小板增多症(ET)、原发性骨髓纤维化(IMF)3种MPN亚型中的发生率及其与疾病转化的相关性。结果 (1)134例MPN患者中PV 51例、ET 66例、IMF 17例,存在JAK2V617F基因突变98例(73.1%),且在PV中发生率(84.3%)高于ET(69.7%)及IMF(52.9%)的发生率(P<0.05),而后两者比较差异无统计学意义(P>0.05)。汉族与维吾尔族突变率比较,差异无统计学意义(P>0.05),在55例维吾尔族患者中,JAK2V617F基因突变的发生率在3种疾病的分布与总体一致,PV(93.8%)高于ET(60.0%)和IMF(33.3%)(P<0.05),后两者比较差异无统计学意义(P>0.05)。(2)134例MPN患者中发生疾病转化者12例(8.9%),其中PV转骨髓纤维化(MF)7例,ET转MF 3例,PV转ET 1例,MF转急性白血病1例。JAK2V617F基因突变阳性者发生疾病转化8例(8.2%);突变阴性者发生转化4例(11.1%),差异无统计学意义(P>0.05)。结论 MPN患者JAK2V617F基因突变发生率与疾病类型有关,且维吾尔族患者也符合基因突变发生率在疾病中的分布规律。MPN患者疾病可以发生转化,JAK2V617F基因突变与疾病的转化无相关性,因此JAK2V617F基因突变对MPN尤其是PV的诊断有一定帮助,但对疾病转化及预后是否有提示性有待于进一步研究证实。 Objective To investigate the correlation between JAK2V617F mutation and the disease classification and conversions in patients with myeloproliferative neoplasm (MPN) in Xinjiang area. Methods The JAK2V617F gene was detected in 134 MPN patients. The correlation between JAK2V617F mutation and the MPN classification and conversions were analyzed. Results Of these 134 patients, three MPN subtypes including polythythemia vera (PV) ( n = 51 ), etiologic thrombocy- themia (ET) ( n =66), and idiopathic (primary) myelofibrosis (IMF) ( n = 17) were identified. JAK2V617F mutation was detected in 98 cases (73.1%). The frequency of JAK2V617F mutation in PV patients (84. 3% ) was significantly higher than that in ET (69. 7% ) and IMF (52. 9% ) patients (P 〈 0. 05). The difference between the latter was not significant (P 〉 0. 05). There was no significant difference between JAK2V617F positive and negative patients in terms of ethnic group (P 〉 0. 05 ). In 55 Uyghur patients, the frequency of JAK2V617F mutation showed similar trend: it was significantly higher in PV patients (93.8%) was than in ET (60. 0%) and IMF (33.3%) patients (P 〈0. 05). Among these 134 cases, 12 (8.9%) experienced disease conversions: 7 patients were transverted from PV to MF, 3 from ET to MF, 1 from PV to ET, and 1 from MF to M2a. There was no significant difference in conversions of disease with JAK2V617F mutation or without it. Conclusion JAK2V617F mutation is correlated with the classification of MPN, which is equally seen in Uyghur populations. In addition, MPN can be transformed to others, but the conversions are not correlated with JAK2V617F mutation. Therefore, JAK2V617F mutation may be helpful for the diagnosis of MPN, especially PV.
出处 《中国全科医学》 CAS CSCD 北大核心 2012年第30期3486-3488,共3页 Chinese General Practice
基金 新疆维吾尔自治区科技支疆项目计划(指令性)项目(200991142)
关键词 骨髓增殖性肿瘤 JAK2V617F点突变 疾病转化 Myeloproliferative neoplasm JAK2V617F mutation Disease transformation
  • 相关文献

参考文献12

  • 1Tefferi A ,Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel [J]. Blood, 2007, 110 (4) : 1092 -1097.
  • 2James C, Ugo V, Couedic JPL, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera [ J ]. Nature, 2005, 434 (7037) : 1144 -1148.
  • 3Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myelopmliferative diseases [J]. Lancet, 2005, 365 (9464): 1054-1061.
  • 4Kralovics R, Passamonti F, Buser AS, et al. Again - of - function mutation of JAK2 in myelopmliferative disorders [ J ]. N Engl J Med, 2005, 352:1779 - 1790.
  • 5晁红颖,范峥,张日,沈益民,陈婉,费海荣,朱子玲,冯宇峰,陈子兴,薛永权.412例骨髓增殖性肿瘤的JAK2V617F突变检测及其临床意义[J].中华肿瘤杂志,2009,31(7):510-514. 被引量:9
  • 6王一,左安兰,刘英慧,刘兵城,郝长来,王莉红,周雪丽,钱林生.356例骨髓增殖性疾病的相互转化及其并发症[J].中华血液学杂志,2002,23(6):314-317. 被引量:8
  • 7Talarico L, Wolf BC, Kumar A, et al. Reversal bone marrow fibrosis and subsequent development of polycythemia in patients with myeloproliferative disorders [J]. Am J Hematol, 1989, 30 (4) : 248 -253.
  • 8Jantunen R, Juvonen E, Ikkala E, et al. Development of erythrocytosis in the course of essential thrombocythemia [J]. Ann Hematol, 1999, 78 (5): 219-222.
  • 9Randi ML, Fabris F, Girolami A. Leukemia and myelodysPlasia effect of multiple cytotoxic therapy in essential thrombocythemia [ J ]. Leuk Lymphoma, 2000, 37 (3/4): 379-85.
  • 10Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutationin JAK2 is associated with poorer survival inidiopathie myelofibrosis [ J]. Blood, 2005, 107 (5): 2098-2100.

二级参考文献14

  • 1Baxter EJ, Scott LM, Campbell P J, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet, 2005, 365 : 1054-1061.
  • 2James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitative signalling causes polycythaemia vera. Nature, 2005, 434:11444-1148.
  • 3Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N EngI J Med, 2005, 352 : 1779-1790.
  • 4Tefferi A,Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms :The 2008 World Health Organization criteria and point- of-care diagnostic algorithms. Leukemia, 2008, 22:14-22.
  • 5Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases//Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors : Turnouts of the Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer ( IARC ) Press, 2001 : 17-44.
  • 6Campbell PJ, Scott LM, Baxter FA, et al. Methods for the detection of the JAK2V617F mutation in human myeloproliferative disorders. Methods Mol Med, 2006, 109:253-264.
  • 7Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia : interaction with treatment, standard risk factors, and Jak2 mutation status. Blood, 2007, 109:2310-2313.
  • 8Campbell PJ, Baxter E J, Beer PA, et al. Mutation of JAK2 in the myeloproliferati ve disorders : timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood, 2006, 108 : 3548-3555.
  • 9Michiels JJ. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond. Hematology, 2005, 10 suppl 1:215-223.
  • 10Schafer AI. Molecular basis of the diagnosis and treatment of polycythenia vera and essential thrombocythemia. Blood, 2006, 107: 4214- 4222.

共引文献15

同被引文献96

  • 1张俊美,王畅,王轶卓,姚程.初治结肠癌合并骨髓增生异常综合征1例[J].中国老年学杂志,2014,34(1):215-217. 被引量:1
  • 2肖静,牛文钰,滕伟.聚酰胺-胺对白色念珠菌和牙龈卟啉单胞菌的抗菌性研究[J].中华口腔医学杂志,2011,46(1):94-98.
  • 3Postigo A, Bulacio L, Sortino M. Photodynamic inactivation of oropharyngeal Candida strains [J]. Phytomedicine,2014, 7113 (14) : 212-218.
  • 4Chang HT,Tsai PW,Huang HH,et al. LL37 and hBD-3 elevate the β-1,3-exoglucanase activity of Candida albi- cans Xoglp, resulting in reduced fungal adhesion to plas- tic [J]. Biochem J,2012,441 (3) :963-970.
  • 5Obokata H,Yamato M,Yang J,et al. Subcutaneous trans- plantation of autologous oral mucosal epithelial cell sheets fabricated on temperature-responsive culture dish- es [J]. J Biomed Mater Res A,2008,86(4) :1088-1096.
  • 6Martinez RC,Seney SL,Summers KL,et al. Effect of Lac- tobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and induce inflammation [J]. Microbiol Immunol,2009,53 (9) :487-495.
  • 7Trabocchi A,Mannino C,Machetti F,et al. Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds [J]. J Med Chem,2010,53 (6) :2502-2509.
  • 8James C,Ugo V,Le Couedic JP, et al. A unique clonal JAK2 mutationleading to Constitutive signaling causes polycythemia vera [ J ]. Na-ture, 2005 ,434(7037) :1144-1148.
  • 9Levine RL,Wadleigh M,Cools J,et al. Activating mutation of the tyro—sine Kinase JAK2 in Polycythemia vera,essential thrombocythe-mia,and Myeloid Metaplasia with myelofibrosis [ J ]. Cancer Cell,2005,7(4) :387 -397.
  • 10Baxter EJ,Scott LM,Campbell PJ,et al. Acquired mutation of the tyro—sine Kinase JAK2 in human myeloproliferative disorders [ J ]. TheLancet,2005,365(9464) : 1054 -1061.

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部